Future Therapies

Asthma and COPD

Volumn , Issue , 2009, Pages 737-749

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72049086307     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374001-4.00061-4     Document Type: Chapter

References (118)

1. Barnes PJ Immunology of asthma and chronic obstructive pulmonary disease. Nat Immunol Rev 2008, 8:183-192.
2. Barnes PJ New therapies for asthma. Trends Mol Med 2006, 12:515-520.
3. Barnes PJ, Hansel TT Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004, 364:985-996.
4. Holgate ST, Polosa R Treatment strategies for allergy and asthma. Nat Rev Immunol 2008, 8:218-230.
5. Horne R Compliance, adherence, and concordance: Implications for asthma treatment. Chest 2006, 130:65S-72S.
6. Barnes PJ Chronic obstructive pulmonary disease: A growing but neglected epidemic. PLoS Med 2007, 4:e112.
7. Barnes PJ,.Stockley RA COPD: Current therapeutic interventions and future approaches. Eur Respir J 2005, 25:1084-1106.
8. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
9. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:6-14.
10. Sturton G, Persson CGA, Barnes PJ Small airways: An important but neglected target in obstructive airway diseases. Trends in Pharmacol Sci 2008, (in press).
11. Roses AD Pharmacogenetics and future drug development and delivery. Lancet 2000, 355:1358-1361.
12. Matera MG, Cazzola M Ultra-long-acting beta2-adrenoceptor agonists: An emerging therapeutic option for asthma and COPD?. Drugs 2007, 67:503-515.
13. Laforce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, et al. Indacaterol provides sustained 24h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study. Allergy 2008, 63:103-111.
14. Sturton RG, Nicholson AG, TrifilieffA, Barnes PJ Pharmacological characterisation of indacaterol, a novel once-daily inhaled b2-adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008, 324:270-275.
15. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005, 128:1974-1979.
16. Joos GF, Schelfhout VJ, Kanniess F Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: A phase II study. Eur Resp J 2007.
17. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
18. Barnes PJ, Chung KF, Page CP Inflammatory mediators of asthma: An update. Pharmacol Rev 1998, 50:515-596.
19. Barnes PJ Mediators of chronic obstructive pulmonary disease. Pharm Rev 2004, 56:515-548.
20. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 2007, 370:1422-1431.
21. Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt RW, et al. TSLP: An epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 2007, 25:193-219. 193-219.
22. Panina-Bordignon P, D'Ambrosio D Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2003, 9:104-110.
23. Donnelly LE, Barnes PJ Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006, 27:546-553.
24. O'Connor BJ, Leaker BR, Barnes PJ, Nicholson G, Grahames C, Larsson B, et al. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers. Eur Resp J 2007, 30(Suppl 51):1294.
25. Costa C, Rufino R, Traves SL, Lapa E, Silva JR, Barnes PJ, Donnelly LE CXCR3 and CCR5 chemokines in the induced sputum from patients with COPD. Chest 2008, 133:26-33.
26. Rahman I, Biswas SK, Kode A Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006, 533:222-239.
27. Barnes PJ Reduced histone deacetylase in COPD: Clinical implications. Chest 2006, 129:151-155.
28. Kirkham P, Rahman I Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol Ther 2006, 111:476-494.
29. Reed CE, Kita H The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol 2004, 114:997-1008.
30. Clark JM, Abraham WM, Fishman CE, Forteza R, Ahmed A, Cortes A, et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 1995, 152:2076-2083.
31. Krishna MT, Chauhan A, Little L, Sampson K, Hawksworth R, Mant T, et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001, 107:1039-1045.
32. Erin EM, Leaker BR, Zacharasiewicz A, Higgins LA, Nicholson GC, Boyce MJ, et al. Effects of a reversible b-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin Exp Allergy 2006, 36:458-464.
33. Luisetti M, Sturani C, Sella D, Madonini E, Galavotti V, Bruno G, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996, 9:1482-1486.
34. Hu J, Van Den Steen PE, Sang QX, Opdenakker G Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007, 6:480-498.
35. Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007, 62:706-713.
36. Barnes PJ, Adcock IM How do corticosteroids work in asthma?. Ann Intern Med 2003, 139:359-370.
37. Reynolds NA, Scott LJ Ciclesonide. Drugs 2004, 64:511-519.
38. Barnes PJ How corticosteroids control inflammation. Br J Pharmacol 2006, 148:245-254.
39. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004, 101:227-232.
40. Rosen J, Miner JN The search for safer glucocorticoid receptor ligands. Endocr Rev 2005, 26:452-464.
41. Lipworth BJ Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005, 365:167-175.
42. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005, 172:848-853.
43. Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006, 61:72-78.
44. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087.
45. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:154-1061.
46. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: Predominant role of PDE4D. J Immunol 2007, 178:4820-4831.
47. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, et al. Discovery of BRL 50481, a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages and CD8+ T-lymphocytes. Mol Pharmacol 2004, 66:1679-1689.
48. Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, Collins M, et al. IkappaB kinase-2-independent and -dependent inflammation in airway disease models: Relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006, 69:1791-1800.
49. Tudhope SJ, Catley MC, Fenwick PS, Russell RE, Rumsey WL, Newton R, et al. The role of IkB kinase 2, but not activation of NF-kB, in the release of CXCR3 ligands from IFN-g-stimulated human bronchial epithelial cells. J Immunol 2007, 179:6237-6245.
50. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008, 31:62-69.
51. Maneechotesuwan K, Xin Y, Ito K, Jazrawi E, Lee KY, Usmani OS, et al. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol 2007, 178:2491-2498.
52. Kankaanranta H, Giembycz MA, Barnes PJ, Lindsay DA SB203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 1999, 290:621-628.
53. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005, 171:571-578.
54. Matthews JG, Ito K, Barnes PJ, Adcock IM Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004, 113:1100-1108.
55. Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006, 149:393-404.
56. Medicherla S, Fitzgerald M, Spicer D, Woodman P, Ma JY, Kapoun AM, et al. p38a selective MAP kinase inhibitor, SD-282, reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2007.
57. Tudhope SJ, Finney-Hayward TK, Nicholson AG, Mayer RJ, Barnette MS, Barnes PJ, et al. Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 2008, 324:306-312.
58. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira dSA, Stanford WL, Bolon B, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000, 287:1040-1046.
59. Medina-Tato DA, Ward SG, Watson ML Phosphoinositide 3-kinase signalling in lung disease: Leucocytes and beyond. Immunology 2007, 121:448-461.
60. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003, 10:207-213.
61. Spears M, McSharry C, Thomson NC Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006, 36:1494-1504.
62. Belvisi MG, Hele DJ, Birrell MA Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006, 533:101-109.
63. Remels AH, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker HR, et al. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 2007, 30:245-252.
64. Costello PS, Turner M, Walters AE, Cunningham CN, Bauer PH, Downward J, et al. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene 1996, 13:2595-2605.
65. YousefiS, Hoessli DC, Blaser K, Mills GB, Simon HU Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 1996, 183:1407-1414.
66. Wong BR, Grossbard EB, Payan DG, Masuda ES Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 2004, 13:743-762.
67. Stenton GR, Ulanova M, Dery RE, Merani S, Kim MK, Gilchrist M, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002, 169:1028-1036.
68. Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006, 173:56-63.
69. Meltzer EO, Berkowitz RB, Grossbard EB An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005, 115:791-796.
70. Amoui M, Draber P, Draberova L Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells. Eur J Immunol 1997, 27:1881-1886.
71. Pilewski JM, Albelda SM Cell adhesion molecules in asthma: homing activation and airway remodelling. Am J Respir Cell Mol Biol 1995, 12:1-3.
72. Weg VB, Williams TJ, Lobb RR, Noorshargh S A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. J Exp Med 1993, 177:561-566.
73. Yuan Q, Strauch KL, Lobb RR, Hemler ME Intracellular single-chain antibody inhibits integrin VLA-4 maturation and function. Biochem J 1996, 318:591-596.
74. Lin Kc, Ateeq HS, Hsiung SH, Chong LT, Zimmerman CN, Castro A, et al. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J Med Chem 1999, 42:920-934.
75. Okigami H, Takeshita K, Tajimi M, Komura H, Albers M, Lehmann TE, et al. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Eur J Pharmacol 2007, 559:202-209.
76. Abraham WM, Ahmed A, Sabater JR, Lauredo IT, Botvinnikova Y, Bjercke RJ, et al. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med 1999, 159:1205-1214.
77. Kogan TP, Dupre B, Bui H, McAbee KL, Kassir JM, Scott IL, et al. Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269). J MedChem 1998, 41:1099-1111.
78. Lock SH, Kay AB, Barnes NC Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996, 153:509-514.
79. Morley J Cyclosporin A in asthma therapy: A pharmacological rationale. J Autoimmun 1992, 5(Suppl A):265-269.
80. Morishita Y, Hirayama Y, Miyayasu K, Tabata K, Kawamura A, Ohkubo Y, et al. FK506 aerosol locally inhibits antigen-induced airway inflammation in Guinea pigs. Int Arch Allergy Immunol 2005, 136:372-378.
81. Grumelli S, Corry DB, Song L-X, Song L, Green L, Huh J, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004, 1:75-83.
82. Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, Changelian P The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008, 582:154-161.
83. Haczku A, Takeda K, Redai I, Hamelmann E, Cieslewicz G, Joetham A, et al. Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice [In Process Citation]. Am J Respir Crit Care Med 1999, 159:1638-1643.
84. Van Oosterhout AJ, Hofstra CL, Shields R, Chan B, van Ark I, Jardieu PM, et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1997, 17:386-392.
85. van Neerven RJ, Van de Pol MM, van der Zee JS, Stiekema FE, De Boer M, Kapsenberg ML Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression [see comments]. Clin Exp Allergy 1998, 28:808-816.
86. Kon OM, Compton CH, Kay AB, Barnes NC A dopuble-blind placebo-controlled trial of an anti-CD4 monoclonal antibody SB210396. Am J Respir Crit Care Med 1997, 155:A203.
87. Schwarze J, Cieslewicz G, Joetham A, Ikemura T, Hamelmann E, Gelfand EW CD8λT cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J Immunol 1999, 162:4207-4211.
88. Tamaoki J, Kondo M, Sakai N, Aoshiba K, Tagaya E, Nakata J, et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: A double-blind randomised study. Lancet 2000, 356:273-278.
89. Gomes B, Cabral MD, Gallard A, Savignac M, Paulet P, Druet P, et al. Calcium channel blocker prevents T helper type 2 cell-mediated airway inflammation. Am J Respir Crit Care Med 2007, 175:1117-1124.
90. Maneechotesuwan K, Supawita S, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. J Allergy Clin Immunol 2008, 121:43-50.
91. Larche M Regulatory T cells in allergy and asthma. Chest 2007, 132:1007-1014.
92. Smyth LJ, Starkey C, Vestbo J, Singh D CD4-regulatory cells in COPD patients. Chest 2007, 132:156-163.
93. Akdis M, Blaser K, Akdis CA T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005, 116:961-968.
94. Larche M Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007, 119:906-909.
95. Pers JO, Daridon C, Bendaoud B, Devauchelle V, Berthou C, Saraux A, et al. B-cell depletion and repopulation in autoimmune diseases. Clin. Rev Allergy Immunol 2008, 34:50-55.
96. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
97. Rosenwasser LJ, Meng J Anti-CD23. Clin Rev Allergy Immunol 2005, 29:61-72.
98. Wohlleben G, Erb KJ Atopic disorders: A vaccine around the corner?. Trends Immunol 2001, 22:618-626.
99. Krieg AM Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
100. Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O'Byrne PM Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006, 174:15-20.
101. Feleszko W, Jaworska J, Hamelmann E Toll-like receptors-novel targets in allergic airway disease (probiotics, friends and relatives). Eur J Pharmacol 2006, 533:308-318.
102. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, CD002991.
103. Hew M, Bhavsar P, Torrego A, Meah S, Khorasani N, Barnes PJ, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006, 174:134-141.
104. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kB suppression. J Exp Med 2006, 203:7-13.
105. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004, 200:689-695.
106. Barnes PJ Theophylline for COPD. Thorax 2006, 61:742-743.
107. Fox JC, Spicer D, Ito K, Barnes PJ, Fitzgerald MF Oral or inhaled corticosteroid combination therapy with low dose theophylline reverses corticosteroid insensitivity in a smoking mouse model. Proc Am Thorac Soc 2007, A637.
108. Rubin BK, Henke MO Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004, 125:70S-78S.
109. Charron C, Sumakuza T, Oomura S, Ito K EM-703, a non-antibacterial erythromycin derivative, restores HDAC2 activition diminished by hypoxia and oxidative stress. Proc Am Thorac Soc 2007.
110. Prud'homme GJ Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007, 87:1077-1091.
111. Maden M, Hind M Retinoic acid in alveolar development, maintenance and regeneration. Philos Trans R Soc Lond B Biol Sci 2004, 359:799-808.
112. Roth MD, Connett JE, D'Armiento JM, Foronjy RF, Friedman PJ, Goldin JG, et al. Feasibility of retinoids for the treatment of emphysema study. Chest 2006, 130:1334-1345.
113. Wang D, Haviland DL, Burns AR, Zsigmond E, Wetsel RA A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2007, 104:4449-4454.
114. Loebinger MR, Janes SM Stem cells for lung disease. Chest 2007, 132:279-285.
115. Cookson WO State of the art, Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:473-475.
116. Hall IP, Sayers I Pharmacogenetics and asthma: False hope or new dawn?. Eur Respir J 2007, 29:1239-1245.
117. Xing Z, Ohkawara Y, Jordana M, Grahern FL, Gauldie J Transfer of granulocyte-macrophage colony-stinulating factor gene to rat induces eosinophilia, monocytosis and fibrotic lesions. J Clin Invest 1996, 97:1102-1110.
118. Metzger WJ, Nyce JW Oligonucleotide therapy of allergic asthma. J Allergy Clin Immunol 1999, 104:260-266.